ArticleSao Paulo medical journal = Revista paulista de medicina2019
Secondary prevention of coronary heart disease: a cross-sectional analysis on the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
Article in Sao Paulo medical journal = Revista paulista de medicina, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis.Global heart · 2022Pooled it
- Systematic review of cardiovascular care delivery across health systems in the Asia-Pacific: a regional roadmap for strengthening cardiovascular care.The Lancet regional health. Western Pacific · 2026Article
- Acute Coronary Syndrome in Brazil: Registration of Predisposing Factors and Population Profile in a National Public Reference Cardiological Institute.Arquivos brasileiros de cardiologia · 2025Article
- Cardiovascular Statistics - Brazil 2023.Arquivos brasileiros de cardiologia · 2024Article
- A Global Perspective on Cardiovascular Risk Factors by Educational Level in CHD Patients: SURF CHD II.Global heart · 2024Article
- Secondary Pharmacological Prevention of Coronary Artery Disease among Patients Submitted to Clinical Management, Percutaneous Coronary Intervention, or Coronary Artery Bypass Graft Surgery.Arquivos brasileiros de cardiologia · 2023Article
- Cardiovascular Statistics - Brazil 2021.Arquivos brasileiros de cardiologia · 2022Article
- The Prognosis of Coronary Artery Disease in a Brazilian Community Hospital: Findings from the ERICO Study.Arquivos brasileiros de cardiologia · 2021Article
- Prevalence of pharmacological adherence in patients with coronary artery disease and associated factors.Revista latino-americana de enfermagem · 2021Article
- Subclinical thyroid diseases as a non-classical risk factor for cardiovascular diseases.Sao Paulo medical journal = Revista paulista de medicina · 2020Article
- Secondary prevention of cardiovascular disease in Brazil: lessons from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).Sao Paulo medical journal = Revista paulista de medicinaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary heart disease (CHD) remains a major cause of mortality worldwide and in Brazil. Use of standard medications after CHD has been proven to avoid new events and reduce early mortality.
objectivesThis study aimed to analyze secondary prevention of CHD and its association with the baseline characteristics of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). DESIGN AND
settingCross-sectional analysis on ELSA-Brasil data.
methodsSecondary prevention of CHD recommended in standard guidelines (antiplatelet plus beta-blocker plus lipid-lowering drug, with or without angiotensin-converting enzyme inhibitors, ACEI, or angiotensin receptor blockers, ARB) was evaluated in relation to sociodemographic data and the time since the coronary event. The chi-square test, one-way analysis of variance (ANOVA) and Mann-Whitney test were performed, as necessary.
resultsAmong 15,094 participants, 2.7% reported a previous diagnosis of CHD. Use of recommended drugs for secondary prevention was reported by almost 35% of the participants. Medication use for secondary prevention was generally more frequent among high-income participants than among low-income participants. Use of ARB and ACEI was different between participants who had private health insurance and those who only used the public healthcare system. Men were more likely to use medication than women. The frequency with which participants used the recommended drugs was similar in all time periods after CHD, but use of only one drug increased progressively across time periods.
conclusionThe use of medication for secondary prevention of CHD was lower than what is recommended in standardized guidelines, especially among women and lower-income participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.